



## PRESS RELEASE

### Active Biotech to Present at the UBS Global Life Sciences Conference

**Lund, Sweden, September 16, 2010 - Active Biotech (NASDAQ OMX Nordic: ACTI)** is scheduled to present at the UBS Global Life Sciences Conference held September 20-22, 2010 at the Grand Hyatt New York, New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided.

The presentation will include projects in or entering Phase III; **laquinimod**, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical Industries Ltd, the prostate cancer project **TASQ** and **ANYARA**, Active Biotech's novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, the project **57-57** and the pre-clinical **ISI** project will be presented.

The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to – [www.activebiotech.com](http://www.activebiotech.com).

The presentation will take place on **September 22, at 12:00 pm US Eastern Daylight Time / 18.00 Central European Summer Time.**

#### **About Active Biotech**

*Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex™ for RA. Please visit [www.activebiotech.com](http://www.activebiotech.com) for more information.*

*Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CEST on September 16, 2010.*

#### **Contacts:**

##### **Active Biotech AB**

Göran Forsberg, VP Investor Relations & Business Development  
P.O. Box 724, SE-220 07 Lund, Sweden  
Tel: +46 (0)46-19 20 00  
Fax: +46 (0)46-19 11 00